(primary solid tumor cohort)
This pipeline uses various statistical tests to identify miRs whose expression levels correlated to selected clinical features.
Testing the association between 534 miRs and 5 clinical features across 482 samples, statistically thresholded by Q value < 0.05, 2 clinical features related to at least one miRs.
-
4 miRs correlated to 'Time to Death'.
-
HSA-MIR-222 , HSA-MIR-221 , HSA-MIR-148A , HSA-MIR-34A
-
3 miRs correlated to 'AGE'.
-
HSA-MIR-148A , HSA-MIR-210 , HSA-MIR-339
-
No miRs correlated to 'GENDER', 'KARNOFSKY.PERFORMANCE.SCORE', and 'RADIATIONS.RADIATION.REGIMENINDICATION'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=4 | shorter survival | N=4 | longer survival | N=0 |
AGE | Spearman correlation test | N=3 | older | N=3 | younger | N=0 |
GENDER | t test | N=0 | ||||
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=0 | ||||
RADIATIONS RADIATION REGIMENINDICATION | t test | N=0 |
Time to Death | Duration (Months) | 0.1-127.6 (median=10.3) |
censored | N = 103 | |
death | N = 379 | |
Significant markers | N = 4 | |
associated with shorter survival | 4 | |
associated with longer survival | 0 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
HSA-MIR-222 | 1.27 | 6.105e-09 | 3.3e-06 | 0.563 |
HSA-MIR-221 | 1.32 | 1.292e-06 | 0.00069 | 0.554 |
HSA-MIR-148A | 1.21 | 2.856e-05 | 0.015 | 0.564 |
HSA-MIR-34A | 1.2 | 7.211e-05 | 0.038 | 0.54 |
AGE | Mean (SD) | 57.53 (15) |
Significant markers | N = 3 | |
pos. correlated | 3 | |
neg. correlated | 0 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-148A | 0.2148 | 1.933e-06 | 0.00103 |
HSA-MIR-210 | 0.1952 | 1.587e-05 | 0.00846 |
HSA-MIR-339 | 0.1809 | 6.511e-05 | 0.0346 |
GENDER | Labels | N |
FEMALE | 186 | |
MALE | 296 | |
Significant markers | N = 0 |
No miR related to 'KARNOFSKY.PERFORMANCE.SCORE'.
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 77.61 (14) |
Significant markers | N = 0 |
-
Expresson data file = GBM-TP.mirna__h_mirna_8x15k__unc_edu__Level_3__unc_DWD_Batch_adjusted__data.data.txt
-
Clinical data file = GBM-TP.clin.merged.picked.txt
-
Number of patients = 482
-
Number of miRs = 534
-
Number of clinical features = 5
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.